| Literature DB >> 20447422 |
Jae-Sung Yu1, Ben-Jiang Ma, Richard M Scearce, Hua-Xin Liao, Barton F Haynes.
Abstract
Monoclonal antibodies (MAbs) were developed against soluble Ebola virus (EBOV) envelope glycoprotein (GP) for the study of the diversity of EBOV envelope and development of diagnostic reagents. Of the three anti-EBOV GP mouse MAbs produced, MAb 15H10 recognized all human EBOV GP species tested (Zaire, Sudan, Ivory Coast), and as well as reacted with the Reston nonhuman primate EBOV GPs. A second MAb, 6D11 recognized EBOV GP species of Sudan and Sudan-Gulu. The third MAb, 17A3, was reported originally in the same article to be EBOV GP specific has now been found to be specific for bovine and human alpha-2-macroglobulin (alpha-2M) proteins which were contaminants in the Ebola envelope protein preparation. Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb. Copyright 2010 Elsevier B.V. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20447422 PMCID： PMC2910138 DOI： 10.1016/j.jviromet.2010.04.025
Source DB: PubMed Journal: J Virol Methods ISSN： 0166-0934 Impact factor: 2.014